SuperworthSummit Therapeutics market cap SMMT
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $12.3B
- Highest close in our data
- $23.1B
- Sep 2024
Summit Therapeutics is worth $12.3B at the close on Oct 23, 2026, at $15.47 a share.
That is down 14% over the last year and up 2356% over five years.
Its highest close in our data was $23.1B in Sep 2024.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $12.3B | $10.4B | $19.5B | −9% |
| 2025 | $13.5B | $12.1B | $21.3B | +1% |
| 2024 | $13.4B | $1.8B | $23.1B | +634% |
| 2023 | $1.8B | $310M | $1.8B | +114% |
| 2022 | $855.6M | $87.4M | $855.6M | +226% |
| 2021 | $262.9M | $262.9M | $822.7M | −32% |
| 2020 | $386.6M | $221.3M | $1.6B | +56% |
| 2019 | $248.6M | $92M | $320.8M | +170% |
| 2018 | $92M | $86.1M | $1B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Summit Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| SMMTSummit Therapeutics | $12.3B |
| JAZZJazz Pharmaceuticals | $13.9B |
| BMRNBiomarin Pharmaceutical | $10.8B |
| CORTCorcept Therapeutics | $9.3B |
| PTGXProtagonist Therapeutics | $9B |
| TGTXTG Therapeutics | $8.3B |
| ALKSAlkermes plc. | $7.3B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LGNDLigand Pharmaceuticals | $6.1B |
| KNSAKiniksa Pharmaceuticals International | $6B |
| BIIBBiogen | $37B |
| Peer median | $8.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Summit Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.